Brain MR Spectroscopic Findings in 3 Consecutive Patients with COVID-19: Preliminary Observations


AJNR Am J Neuroradiol published online 29 October 2020
http://www.ajnr.org/content/early/2020/10/29/ajnr.A6877
Brain MR Spectroscopic Findings in 3 Consecutive Patients with COVID-19: Preliminary Observations


ABSTRACT

SUMMARY: Brain multivoxel MR spectroscopic imaging was performed in 3 consecutive patients with coronavirus disease 2019 (COVID-19). These included 1 patient with COVID-19-associated necrotizing leukoencephalopathy, another patient who had a recent pulseless electrical activity cardiac arrest with subtle white matter changes, and a patient without frank encephalopathy or a recent severe hypoxic episode. The MR spectroscopic imaging findings were compared with those of 2 patients with white matter pathology not related to Severe Acute Respiratory Syndrome coronavirus 2 infection and a healthy control subject. The NAA reduction, choline elevation, and glutamate/glutamine elevation found in the patient with COVID-19-associated necrotizing leukoencephalopathy and, to a lesser degree, the patient with COVID-19 postcardiac arrest, follow a similar pattern as seen with the patient with delayed posthypoxic leukoencephalopathy. Lactate elevation was most pronounced in the patient with COVID-19 necrotizing leukoencephalopathy.

ABBREVIATIONS: COVID-19 = coronavirus disease 2019; DPL = delayed posthypoxic leukoencephalopathy; Lac = lactate; PEA = pulseless electrical activity; SAE = sepsis-associated encephalopathy; SARS-CoV-2 = Severe Acute Respiratory Syndrome coronavirus 2

Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 11, 2020.1 COVID-19 primarily affects the lower respiratory tract, but many organs can be involved, including the central nervous system.2,3 Neurologic manifestations of SARS-CoV-2 infection are increasingly reported and include cerebrovascular complications, leukoencephalopathy, and other CNS disorders.4 Although COVID-19-associated white matter abnormalities resemble other forms of diffuse white matter injury (such as posthypoxic leukoencephalopathy or sepsis-associated leukoencephalopathy), there are also notable differences, such as the neuroanatomic distribution of white matter lesions. The pathogenesis of COVID-19 white matter abnormalities remains unknown, though “silent hypoxia” has been hypothesized to have a central role in their development.5,6

MR spectroscopy represents a noninvasive in vivo diagnostic tool for evaluating white matter injury and can provide valuable information regarding the underlying pathogenesis of white matter pathologies. In the setting of diffuse white matter injury, MR spectroscopy offers a complementary evaluation to structural MR brain imaging by providing a sensitive measurement of various in vivo metabolites. Most important, MR spectroscopy can identify neurochemical abnormalities even in the absence of corresponding findings on structural MR brain imaging.7,8

The metabolic profile of COVID-19-associated leukoencephalopathy using MRS has not been well established in the literature to date. We present examples of MR spectra in patients with COVID-19 and compare them with both other patients with leukoencephalopathy and a control.

Case Series

Six 3D multivoxel MRS datasets from 3 patients with COVID-19 (Fig 1 and Table 1), 2 control patients with leukoencephalopathy (posthypoxic and sepsis-related leukoencephalopathy), and 1 healthy age-matched control were acquired using 3T MR imaging scanners (Siemens, Erlangen, Germany). This 3D-MRS sequence was acquired using a Localization by Adiabatic Selective Refocusing (LASER) pulse sequence with a fast spiral k-space acquisition.9 Acquisition parameters included the following: TE = 30 ms and 288 ms (except for the control and patient with delayed
posthypoxic leukoencephalopathy [DPL]), TR = 1500 ms, Number of Acquisitions = 5, isotropic resolution 1 cc. Excitation VOIs were placed using FLAIR or T2-weighted images to include the white matter abnormalities.

Raw data files were processed using the LCModel software package, Version 6.3 (http://www.lcmodel.com/) with the appropriate basis set. For the data analysis, 6–8 white matter MR spectroscopy voxels of the section with the most prominent white matter abnormalities were averaged, and their metabolite ratios were compared.

Of the patients with COVID-19, 1 patient had MR imaging findings compatible with a necrotizing leukoencephalopathy with abnormal reduced diffusivity and cavitation within the white matter. The patient had COVID-19-associated multifocal necrotizing leukoencephalopathy, showing diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well as elevated Lac. A patient with COVID-19 after recent PEA cardiac arrest with subtle FLAIR hyperintense white matter changes also shows elevated Cho/Cr and decreased NAA/Cr ratios. However, these derangements are less severe than in the patient in A. There is no clear elevation of Lac. A patient with COVID-19 without encephalopathy or recent severe hypoxia has normal Cho/Cr, with mildly decreased NAA/Cr and no lactate elevation. Cho, Choline; NAA, N-Acetyl-Aspartate; ml, Myo-Inositol; Lac, Lactate; Glx, Glutamate + Glutamine.

Table 1: Demographics and clinical information

<table>
<thead>
<tr>
<th>Subject</th>
<th>Diagnosis</th>
<th>Status</th>
<th>Age (yr)</th>
<th>Sex</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-A</td>
<td>COVID-19-related multifocal necrotizing leukoencephalopathy</td>
<td>ICU and intubated</td>
<td>63</td>
<td>M</td>
</tr>
<tr>
<td>COVID-B</td>
<td>COVID-19-related recent PEA cardiac arrest, without clear leukoencephalopathy</td>
<td>ICU and intubated</td>
<td>53</td>
<td>M</td>
</tr>
<tr>
<td>COVID-C</td>
<td>COVID-19 without clear leukoencephalopathy or recent severe hypoxia</td>
<td>Neurology ward and not intubated</td>
<td>72</td>
<td>M</td>
</tr>
<tr>
<td>DPL</td>
<td>Non-COVID-19 delayed posthypoxic/toxic leukoencephalopathy</td>
<td>Neurology ward and not intubated</td>
<td>44</td>
<td>F</td>
</tr>
<tr>
<td>SAE</td>
<td>Non-COVID-19 presumed sepsis-associated encephalopathy</td>
<td>ICU and mechanical ventilation via tracheostomy</td>
<td>55</td>
<td>F</td>
</tr>
<tr>
<td>Control</td>
<td>Healthy volunteer</td>
<td></td>
<td>65</td>
<td>M</td>
</tr>
</tbody>
</table>

Note: ICU indicates intensive care unit.
lesions (COVID-A) (Fig 1A). The second patient had pulseless electrical activity (PEA) arrest while in the intensive care unit and subsequently developed altered mental status. His MR imaging showed cerebellar cortical and hippocampal signal abnormalities suggestive of prior hypoxic-ischemic injury and subtle bilateral cerebellar and supratentorial white matter T2/FLAIR hyperintensities (COVID-B) (Fig 1B). The third patient with COVID-19 without an encephalopathic syndrome had a history of parkinsonism and developed catatonia of unclear etiology (COVID-C) (Fig 1C). This patient’s MR imaging showed mild nonspecific periventricular and deep white matter changes suggestive of small-vessel disease (considering their neuroanatomic distribution). None of these patients were found to have other neurologic comorbidities (eg, other metabolic encephalopathies, hydrocephalus, and so forth).

Data from these 3 patients were contrasted to multivoxel MRS data obtained before the COVID-19 pandemic from 2 patients with other leukoencephalopathies. One patient had DPL and developed severe encephalopathy, rigidity, and mutism, likely related to a prior toxic exposure (opiates) or a hypoxic episode (Fig 2A). The other patient without COVID-19 had sepsis-associated encephalopathy (SAE), with mild diffuse white matter abnormalities on brain MR imaging studies (Fig 2B).

Last, data of all 5 patients with leukoencephalopathy were compared with a dataset acquired using the same protocol from a healthy control subject, a 65-year-old man who volunteered for a research study (Fig 2C).

MRS datasets with short TEs (TE = 30 ms) were analyzed to quantify ratios of NAA, Cho, mi, and Glx relative to Cr. Lactate (Lac)/Cr levels were quantified using MRS datasets with long TEs (TE = 288 ms). Table 2 summarizes the means, SDs, and percentage differences of metabolite levels compared with the control.

Table 2: Mean, SD, and percentage difference relative to controls of brain MRS metabolite ratios in 3 patients with and 3 patients without COVID-19

<table>
<thead>
<tr>
<th>Subject</th>
<th>No. Voxels</th>
<th>NAA/Cr</th>
<th>Cho/Cr</th>
<th>mi/Cr</th>
<th>Glx/Cr</th>
<th>Lac/Cr</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-A</td>
<td>7</td>
<td>0.61 ± 0.13 (−85%)</td>
<td>0.65 ± 0.05 (+80%)</td>
<td>1.17 ± 0.07 (+39%)</td>
<td>1.46 ± 0.20 (+51%)</td>
<td>0.76 ± 0.1</td>
</tr>
<tr>
<td>COVID-B</td>
<td>8</td>
<td>1.10 ± 0.15 (−33%)</td>
<td>0.54 ± 0.04 (+63%)</td>
<td>1.16 ± 0.09 (+38%)</td>
<td>1.40 ± 0.13 (+47%)</td>
<td>0</td>
</tr>
<tr>
<td>COVID-C</td>
<td>6</td>
<td>1.47 ± 0.08 (−5%)</td>
<td>0.27 ± 0.03 (−4%)</td>
<td>1.23 ± 0.10 (−44%)</td>
<td>1.04 ± 0.22 (−18%)</td>
<td>0</td>
</tr>
<tr>
<td>DPL</td>
<td>8</td>
<td>0.81 ± 0.11 (−62%)</td>
<td>0.48 ± 0.02 (+53%)</td>
<td>1.09 ± 0.05 (+32%)</td>
<td>1.82 ± 0.14 (+71%)</td>
<td>0</td>
</tr>
<tr>
<td>SAE</td>
<td>7</td>
<td>0.95 ± 0.16 (−47%)</td>
<td>0.32 ± 0.04 (+13%)</td>
<td>0.61 ± 0.06 (−26%)</td>
<td>1.10 ± 0.12 (+23%)</td>
<td>0</td>
</tr>
<tr>
<td>Control</td>
<td>6</td>
<td>1.54 ± 0.17</td>
<td>0.28 ± 0.04</td>
<td>0.79 ± 0.04</td>
<td>0.87 ± 0.07</td>
<td></td>
</tr>
</tbody>
</table>

a Positive and negative percentages between parentheses indicate percentage difference compared to the control subject.

b Data measured on short-TE (TE = 30 ms) spectra.

c Data measured on long-TE (TE = 288 ms) spectra. No long-TE spectra were available for the DPL and control cases.
d Percentage differences of >30% in magnitude. The distribution of these metabolite ratio derangements in patients with COVID-A (leukoencephalopathy) and COVID-B (post-cardiac arrest) is similar to that of the patient with DPL.

AJNR Am J Neuroradiol 2020 www.ajnr.org

FIG 2. 1H-MR spectra from 2 non-COVID leukoencephalopathy patients, compared with a spectrum from a healthy control patient. Upper row: Axial noncontrast FLAIR (A and B) and T1-weighted (C) images at the level of the corona radiata show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms. A, A patient with delayed posthypoxic/toxic leukoencephalopathy shows an increase of Cho/Cr and decreased NAA/Cr ratios. B, A patient with sepsis-associated encephalopathy shows milder degrees of Cho/Cr elevation and NAA/Cr reduction. C, A healthy control subject with a normal MR spectrum. Cho, Choline; NAA, N-Acetyl-Aspartate; mi, Myo-Inositol; Lac, Lactate; Glx, Glutamate + Glutamine.
Comparative analysis showed decreased NAA/Cr levels within the white matter in 2 of the patients positive for COVID-19 compared with the control. The patient with necrotizing leukencephalopathy (COVID-A) had the most diminished NAA levels, which were completely absent in several MR spectroscopy voxels, followed by the patient with recent cardiac arrest and mild diffuse white matter changes without necrosis (COVID-B). The patient with COVID-C without recent cardiac arrest or overt leukencephalopathy (Fig 1) had slightly decreased NAA/Cr levels compared with the age-matched control. The metabolic profiles of the 3 patients with COVID-19 were contrasted to those of 2 patients with other leukoencephalopathies without COVID-19 (described above) (Fig 2). The NAA/Cr levels of these patients without COVID leukencephalopathy were also decreased but still higher than those in the patient with COVID-A (Table 2).

Compared with the control, 2 of the 3 patients with COVID-19 had elevated Cho/Cr levels (Table 2). The third patient with COVID-19 without leukencephalopathy (COVID-C) showed Cho/Cr levels indistinguishable from those of the control. The patient without COVID-19 with DPL and extensive white matter abnormalities showed increased Cho/Cr ratios, while the patient with SAE had a relatively normal range of Cho/Cr ratios.

All 3 patients with COVID-19 and the patient without COVID-19 with DPL showed elevated ml/Cr levels (Table 2). Most interesting, our patient with sepsis-associated encephalopathy had decreased ml/Cr ratios. Glx/Cr was markedly increased in the 2 patients with COVID-19 with necrotizing leukencephalopathy and after cardiac arrest as well as in the patient without COVID-19 with DPL. Lac/Cr ratios were increased in the patient with COVID-19 with necrotizing leukencephalopathy on long-TE spectra. No elevation of Lac/Cr ratios was seen in the patient with SAE. The patient with DPL and control did not have long-TE spectra. Therefore, we cannot confirm or exclude the presence of lactate in these subjects (Fig 2A).

**DISCUSSION**

Multiple recent reports in the medical literature have confirmed the development of leukencephalopathy as a potential CNS complication in SARS-CoV-2 infection, though no study has reported the MR spectroscopic findings in these patients. We evaluated the metabolic differences among 3 patients with COVID-19 (1 with necrotizing leukencephalopathy, another after cardiac arrest, and the third with mild nonspecific white matter changes without clinical encephalopathy) and other control groups with multivoxel MR spectroscopy to better understand the underlying pathophysiology of this disease. Markedly increased Cho/Cr, decreased NAA/Cr, and increased Lac/Cr ratios were observed in the patient with COVID-19 with multifocal necrotizing leukencephalopathy. Less pronounced changes in Cho/Cr and NAA/Cr ratios were noted in the patient with COVID-19 with prior PEA arrest and subtle nonspecific white matter signal abnormalities. Notably, the magnitude of the Cho and NAA abnormalities in the patient with COVID-19-associated necrotizing leukencephalopathy was more pronounced compared with the patients with delayed post-hypoxic leukencephalopathy and SAE.

In our series, similar patterns of metabolic changes were observed in the setting of COVID-19-associated leukencephalopathy and DPL, namely elevated Cho, elevated Lac, decreased NAA, increased ml, and increased Glx ratios in relation to Cr. This spectral pattern has been previously reported in the setting of DPL following carbon monoxide poisoning or medication overdose. Prolonged impaired oxygenation to the subcortical white matter is thought to promote anaerobic metabolism and leads to elevated tissue Lactate.

The observed increase of Cho/Cr ratios in the patients with leukencephalopathy, particularly in the case of COVID-associated necrotizing leukencephalopathy, likely reflects demyelination within these white matter lesions as recently described in an initial neuropathologic study of a patient with COVID-19. Cho elevation could also be related to cell death and/or immune cellular infiltration within areas of demyelination. Axonal damage was also reported on pathology and likely contributes to the decreased NAA/Cr ratios we observed.

Increased levels of Myo-Inositol (ml) may reflect neuroinflammation, which when coupled with choline elevations in demyelinating pathologies may reflect glial proliferation. The presence of elevated Glx levels has been reported in cases of acute excitotoxic leukencephalopathy and viral-associated acute leukencephalopathy with restricted diffusion. Both conditions are thought to be mediated by excitotoxic injury to the cerebral white matter and exhibit prominent reduced diffusivity within white matter lesions.

Notably, the metabolic derangements seen in the setting of COVID-19-associated multifocal necrotizing leukencephalopathy are similar to those observed with DPL. However, more evidence is required to validate this conclusion. Some of the previously published MR spectroscopy studies of necrotizing encephalopathies from other etiologies also showed increased Lac along with decreased NAA and increased Cho, while others showed Glx and lipid elevations predominantly. Certainly, additional research is warranted in this new field of COVID-19-related metabolic derangement.

The small patient cohort of our study limits our ability to generalize our observations. MRS was only performed in patients with SARS-CoV-2 infection when requested by referring providers for specific clinical indications. Furthermore, the controls without COVID-19 are slightly younger, especially the patient with DPL. Another limitation of our study is that only a single time point was assessed; thus, we cannot exclude other baseline conditions before the SARS-CoV-2 infection, such as chronic small-vessel disease, that may affect our results. Finally, some of these subjects (the patient with DPL and the healthy control) did not have a long-TE MRS acquisition, limiting our ability to unequivocally determine the presence or absence of Lac.

In conclusion, the reported spectroscopic abnormalities within the white matter lesions of COVID-19-associated leukencephalopathy may reflect several pathophysiologic processes, including but not limited to the following: 1) an anaerobic metabolic environment produced by the well-described “silent hypoxia” seen in these patients, resulting in elevation of Lac levels; 2) neuronal dysfunction and axonal injury with decreased NAA/Cr ratios; and 3) increased membrane destruction or turnover with elevated Cho/Cr ratios. Continued data collection in a larger cohort is required to validate these observations and better elucidate their significance in the pathophysiology of SARS-CoV-2 infection.
Disclosures: Otto Rapalino—UNRELATED: Travel and hotel expenses as a lecturer at an event were sponsored by GE Healthcare in August 2019. This lecture did not have any commercial content and did not have any relationship to the current work. Brian L. Edlow—RELATED: Grant; James S. McDonnell Foundation, Comments: McDonnell Foundation COVID-19 Recovery of Consciousness Consortium.* David Fischer—RELATED: Grant; National Institute of Mental Health, Comments: K23MH115812.* Michael H. Lev—RELATED: Consultancy; Takeda Pharmaceutical Company, GE Healthcare, Comments: Consultant; Grants/Pending; National Institutes of Health, Comments: Coinvestigator on 2 technical development grants; Patents (Planned, Pending or Issued): Electrical Impedance Spectroscopy, Artificial Intelligence-related. Eva-Maria Ratai—UNRELATED: Employment; Massachusetts General Hospital, Grants/Pending: National Institutes of Health, National Science Foundation, Comments: R01NS080816, R01HD05762, R01HD083513, U01NS04526, R01DA047088, P01-AT009965, R01CA199903, R01NS12694.* Marco L. Loggia—RELATED: Grant; National Institute of Neurological Disorders and Stroke, Comments: R01NS059537-01A*, UNRELATED: Grants/Pending: National Institutes of Health, Comments: Universidad Rey Juan Carlos, Assistant Professor (September 2019 until now), Massachusetts General Hospital, Research Fellow (August 2017 to August 2019), Grants/Pending: Comunidad de Madrid, MIMC3 PET/MR Project.* Money paid to the institution.

REFERENCES

5. Couzin-Frankel J. The mystery of the pandemic’s ‘happy hypoxia.’ Science 2020;368:455–56 CrossRef Medline